StreetInsider.com News Articles

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

Fri, 06 Feb 2026 08:00:00 -0500

Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards
Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals
Validated system provides reliable, consistent carbon footprint data for clients

INCHEON, South Korea, Feb. 6, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that its product carbon footprint (PCF) system has been validated by Det Norske Veritas (DNV), an independent third-party assurance provider, confirming alignment with globally recognized standards.

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

Fri, 06 Feb 2026 08:00:00 -0500

Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards
Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals
Validated system provides reliable, consistent carbon footprint data for clients

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

Fri, 06 Feb 2026 08:00:00 -0500

Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards
Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals
Validated system provides reliable, consistent carbon footprint data for clients

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

Fri, 06 Feb 2026 08:00:00 -0500

Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards
Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals
Validated system provides reliable, consistent carbon footprint data for clients

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

Fri, 06 Feb 2026 08:00:00 -0500

Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards
Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals
Validated system provides reliable, consistent carbon footprint data for clients

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

Fri, 06 Feb 2026 08:00:00 -0500

Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards
Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals
Validated system provides reliable, consistent carbon footprint data for clients

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

Fri, 06 Feb 2026 08:00:00 -0500

Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards
Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals
Validated system provides reliable, consistent carbon footprint data for clients

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

Fri, 06 Feb 2026 08:00:00 -0500

Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards
Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals
Validated system provides reliable, consistent carbon footprint data for clients

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

Fri, 06 Feb 2026 08:00:00 -0500

Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards
Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals
Validated system provides reliable, consistent carbon footprint data for clients

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

Fri, 06 Feb 2026 08:00:00 -0500

Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards
Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals
Validated system provides reliable, consistent carbon footprint data for clients

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

Fri, 06 Feb 2026 08:00:00 -0500

Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards
Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals
Validated system provides reliable, consistent carbon footprint data for clients

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

Fri, 06 Feb 2026 08:00:00 -0500

Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards
Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals
Validated system provides reliable, consistent carbon footprint data for clients

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

Fri, 06 Feb 2026 08:00:00 -0500

Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards
Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals
Validated system provides reliable, consistent carbon footprint data for clients

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

Fri, 06 Feb 2026 08:00:00 -0500

Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards
Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals
Validated system provides reliable, consistent carbon footprint data for clients

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

Fri, 06 Feb 2026 08:00:00 -0500

Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards
Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals
Validated system provides reliable, consistent carbon footprint data for clients

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

Fri, 06 Feb 2026 08:00:00 -0500

Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards
Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals
Validated system provides reliable, consistent carbon footprint data for clients

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Sun, 21 Dec 2025 17:43:00 -0500

Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network
Additional investments planned to expand the site's capacity (currently at 60,000 liters of drug substance) and capabilities to support growing manufacturing programs
Underscores Samsung Biologics' long-term dedication to the U.S. biopharmaceutical industry and supply chain

INCHEON, South Korea, ROCKVILLE, Md. and LONDON , Dec. 21, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that its wholly owned

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Sun, 21 Dec 2025 17:43:00 -0500

Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network
Additional investments planned to expand the site's capacity (currently at 60,000 liters of drug substance) and capabilities to support growing manufacturing programs
Underscores Samsung Biologics' long-term dedication to the U.S. biopharmaceutical industry and supply chain

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Sun, 21 Dec 2025 17:43:00 -0500

Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network
Additional investments planned to expand the site's capacity (currently at 60,000 liters of drug substance) and capabilities to support growing manufacturing programs
Underscores Samsung Biologics' long-term dedication to the U.S. biopharmaceutical industry and supply chain

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Sun, 21 Dec 2025 17:43:00 -0500

Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network
Additional investments planned to expand the site's capacity (currently at 60,000 liters of drug substance) and capabilities to support growing manufacturing programs
Underscores Samsung Biologics' long-term dedication to the U.S. biopharmaceutical industry and supply chain

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Sun, 21 Dec 2025 17:43:00 -0500

Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network
Additional investments planned to expand the site's capacity (currently at 60,000 liters of drug substance) and capabilities to support growing manufacturing programs
Underscores Samsung Biologics' long-term dedication to the U.S. biopharmaceutical industry and supply chain

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Sun, 21 Dec 2025 17:43:00 -0500

Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network
Additional investments planned to expand the site's capacity (currently at 60,000 liters of drug substance) and capabilities to support growing manufacturing programs
Underscores Samsung Biologics' long-term dedication to the U.S. biopharmaceutical industry and supply chain

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Sun, 21 Dec 2025 17:43:00 -0500

Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network
Additional investments planned to expand the site's capacity (currently at 60,000 liters of drug substance) and capabilities to support growing manufacturing programs
Underscores Samsung Biologics' long-term dedication to the U.S. biopharmaceutical industry and supply chain

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Sun, 21 Dec 2025 17:43:00 -0500

Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network
Additional investments planned to expand the site's capacity (currently at 60,000 liters of drug substance) and capabilities to support growing manufacturing programs
Underscores Samsung Biologics' long-term dedication to the U.S. biopharmaceutical industry and supply chain

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Sun, 21 Dec 2025 17:43:00 -0500

Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network
Additional investments planned to expand the site's capacity (currently at 60,000 liters of drug substance) and capabilities to support growing manufacturing programs
Underscores Samsung Biologics' long-term dedication to the U.S. biopharmaceutical industry and supply chain